title: Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492.
abstract: OBJECTIVE
  This study was performed, in a multi-institutional setting, to evaluate the efficacy and feasibility of the Stanford V chemotherapy regimen plus radiotherapy to bulky Hodgkin's disease sites.
  
  
  METHODS
  A two-stage design was implemented in a phase II study involving 47 patients with bulky mediastinal stage I/II or stage III/IV Hodgkin's disease. Twelve weeks of the Stanford V chemotherapy regimen were given with consolidative radiotherapy (36 Gy) to lymph nodes >/= 5 cm and/or macroscopic splenic disease. Treatment was administered in one of five institutions participating in the Eastern Cooperative Oncology Group.
  
  
  RESULTS
  With a median follow-up of 4.8 years, 45 patients are alive and 40 have been continuously disease-free. The estimated freedom from progression was 87% at 2 years and 85% at 5 years. Overall survival was 96% at 2 and 5 years. There was one death from Hodgkin's disease and one death from an M5 acute leukemia. Six of seven relapsed patients received high-dose therapy and autologous stem-cell transplantation. The freedom from second progression for the seven relapsed patients was estimated at 98% at 3 years.
  
  
  CONCLUSIONS
  Stanford V chemotherapy and consolidative radiotherapy to bulky disease is effective in bulky and advanced Hodgkin's disease in a multi-institutional setting. On this basis, an Intergroup study comparing doxorubicin, bleomycin, vinblastine, and dacarbazine with the Stanford V regimen has been initiated.
authors.affiliation: Department of Medicine, Stanford University Medical Center, Stanford, CA, USA. ml.xsh@forsythe.stanford.edu
authors.forename: S J
authors.initials: SJ
authors.lastname: Horning
authors.forename: J
authors.initials: J
authors.lastname: Williams
authors.forename: N L
authors.initials: NL
authors.lastname: Bartlett
authors.forename: J M
authors.initials: JM
authors.lastname: Bennett
authors.forename: R T
authors.initials: RT
authors.lastname: Hoppe
authors.forename: D
authors.initials: D
authors.lastname: Neuberg
authors.forename: P
authors.initials: P
authors.lastname: Cassileth
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011786:Quality Control; D016019:Survival Analysis; D016896:Treatment Outcome